Levin-M Plus Oral Suspension is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg per dose, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine is a potent, selective antagonist of peripheral H1 histamine receptors, providing rapid relief from symptoms including sneezing, nasal congestion, itching, and rhinorrhea by inhibiting histamine-mediated allergic responses. Montelukast, a leukotriene receptor antagonist, complements this action by blocking cysteinyl leukotriene receptors, thereby reducing inflammation, bronchoconstriction, and mucus production associated with allergic airway diseases. The oral suspension formulation facilitates ease of administration, particularly in pediatric and geriatric populations who may have difficulty swallowing tablets. Levin-M Plus is typically administered once daily, with dosage adjustments based on age and clinical response. It is well tolerated, with a safety profile consistent with its individual components; common adverse effects may include headache, fatigue, and gastrointestinal disturbances. This combination therapy offers a synergistic approach by targeting multiple pathways in allergic inflammation, enhancing symptom control and improving patient quality of life. Levin-M Plus Oral Suspension should be used under medical supervision, with caution in patients with hepatic or renal impairment.